Regenx Tech Downgraded on OTC Markets After Audit Delays
Benzinga reported Sunday that Edmonton-based Regenx Tech Corp. (CSE: RGX / OTCQB: RGXTF) had its U.S. trading symbol quietly shifted from the OTCQB Venture Market to the OTC Expert Market, effective May 18. The company said it received no advance notice and discovered the change only after spotting a corporate action posting.
A Sudden Demotion With No Warning
The reassignment to the OTC Expert Market was not accompanied by any communication from OTC Markets Group, the company said. Regenx only became aware of the change after conducting its own internal review. The move has meaningful consequences for retail investors, as public quotations for RGXTF are no longer broadly visible on standard trading platforms. Access to shares trading on the Expert Market is generally limited to sophisticated or institutional participants.
Cease Trade Order Has Been in Place Since October
The downgrade did not arise in isolation. The Alberta Securities Commission issued a cease trade order against Regenx on October 1, 2025, citing the company’s failure to submit audited annual financial statements, management discussion and analysis, and accompanying certifications for the fiscal year ending March 31, 2025. Those documents were required under Canadian securities law within a set filing window. The Canadian Investment Regulatory Organization subsequently halted trading of Regenx shares on the Canadian Securities Exchange on the same date. That halt remains in force, preventing any domestic Canadian market activity in the stock.
What the Expert Market Means for Shareholders
The OTC Expert Market sits below both the OTCQB and OTCQX tiers in the OTC Markets hierarchy. Companies land there when they fail to meet current information standards. Unlike higher tiers, Expert Market securities cannot be quoted publicly by broker-dealers without specific client instructions. For existing Regenx shareholders in the U.S., selling positions becomes considerably more complicated. The stock was last quoted at $0.03 per share, according to Benzinga data.
Audit Progress and Path Back
Regenx indicated it continues to work toward completing its overdue annual filings. The company has not provided a revised timeline for when those documents might be submitted. Restoration of OTCQB status would require Regenx to first satisfy the ASC’s conditions for lifting the cease trade order, then demonstrate compliance with OTC Markets’ current information requirements. Until those steps are completed, both Canadian and U.S. trading restrictions will remain in place, leaving shareholders with limited options.
Read Next: SEC Tightens Disclosure Rules for Small-Cap Issuers
